Unknown

Dataset Information

0

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.


ABSTRACT: AIM:The PLANET trials showed that atorvastatin 80?mg but not rosuvastatin at either 10 or 40?mg reduced urinary protein to creatinine ratio (UPCR) at similar effects on LDL-cholesterol. However, individual changes in both UPCR and LDL-cholesterol during treatment with these statins varied widely between patients. This inter-individual variability could not be explained by patients' physical or biochemical characteristics. We assessed whether the plasma concentrations of both statins were associated with LDL-cholesterol and UPCR response. MATERIALS AND METHODS:The PLANET trials randomized patients with a UPCR of 500-5000?mg/g and fasting LDL-cholesterol >2.33?mmol/L to a 52-week treatment with atorvastatin 80?mg, rosuvastatin 10 mg or 40?mg. For the current analysis, patients with available samples at week 52 and treatment compliance >80% by pill count were included (N = 295). The main outcome measurements were percentage change in UPCR and absolute change in LDL-cholesterol (delta LDL) from baseline to week 52. RESULTS:Median (interquartile range) plasma concentration at week 52 for atorvastatin 80?mg was 3.9 ng/mL (IQR: 2.1 to 8.7), for rosuvastatin 10 mg 1.0 ng/mL (IQR: 0.7 to 2.0) and for rosuvastatin 40?mg 3.5 ng/mL (IQR: 2.0 to 6.8). Higher plasma concentration of statin was associated with larger LDL-cholesterol reductions at week 52 [rosuvastatin r = -0.40 (P?

SUBMITTER: Kroonen MYAM 

PROVIDER: S-EPMC6900110 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.

Kroonen Marjolein Y A M MYAM   Stevens Jasper J   de Zeeuw Dick D   Heerspink Hiddo J L HJL  

Diabetes, obesity & metabolism 20190930 12


<h4>Aim</h4>The PLANET trials showed that atorvastatin 80 mg but not rosuvastatin at either 10 or 40 mg reduced urinary protein to creatinine ratio (UPCR) at similar effects on LDL-cholesterol. However, individual changes in both UPCR and LDL-cholesterol during treatment with these statins varied widely between patients. This inter-individual variability could not be explained by patients' physical or biochemical characteristics. We assessed whether the plasma concentrations of both statins were  ...[more]

Similar Datasets

2009-11-20 | GSE13689 | GEO
2010-06-19 | E-GEOD-13689 | biostudies-arrayexpress
| S-EPMC8423268 | biostudies-literature
| S-EPMC2656667 | biostudies-literature
| S-EPMC6905000 | biostudies-literature
| S-EPMC5604311 | biostudies-literature
| S-EPMC3793623 | biostudies-literature
2011-09-05 | GSE24188 | GEO
2011-09-05 | GSE24186 | GEO
2011-09-05 | GSE24187 | GEO